Antimitotic Agents: all 5,052 studies that test it
Page 28 of 51. Open to participants first (616), then studies with results posted, then the rest; newest registration first within each.
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedNCT02881086Phase 3
- Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant ChemotherapyStatus unknownNCT02879513Phase 3
- Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)Active, not recruitingNCT02870907Phase 2
- Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.CompletedNCT02866955Phase 2
- Conservative Treatments of RetinoblastomaActive, not recruitingNCT02866136Phase 2
- PAINTER: Polymorphism And INcidence of Toxicity in ERibulin TreatmentCompletedNCT02864030Phase 4
- Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal CarcinomaCompletedNCT02861690Phase 2
- EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
- Metronomic Chemotherapy in Advanced Gastric CancerStatus unknownNCT02855788Phase 2
- Efficacy and Safety of Estracyt® in Metastatic Breast CancerWithdrawnNCT02853071Phase 2
- POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGCCompletedNCT02845908Phase 2
- LBL-2016 for Children or Adolescents in ChinaActive, not recruitingNCT02845882Phase 3
- Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)WithdrawnNCT02845050Phase 1/2
- DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast CancerCompletedNCT02838225Phase 2
- STREAMER : STent Restenosis And MEdicaments ReleaseCompletedNCT02835586Phase 3
- A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung CancerWithdrawnNCT02831491Phase 2
- Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast CancerTerminatedNCT02824575Phase 1
- Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer PatientsCompletedNCT02812992Phase 4
- Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02812667Phase 1
- Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)CompletedNCT02802748Early Phase 1
- Docetaxel Followed by Provenge in Metastatic Prostate CancerWithdrawnNCT02793765Phase 2
- Provenge Followed by Docetaxel in Castration-Resistant Prostate CancerWithdrawnNCT02793219Phase 2
- Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and OverStatus unknownNCT02792491Phase 2
- Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian CancerCompletedNCT02788708Phase 1
- A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung CancerStatus unknownNCT02787473Phase 2
- Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02786641Phase 3
- EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT CancerCompletedNCT02783222Phase 2
- Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerStatus unknownNCT02780778Phase 2/3
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
- Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland CarcinomasCompletedNCT02776163Phase 2
- Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and NeckCompletedNCT02776137Phase 2
- Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast CancerStatus unknownNCT02768415Phase 2
- SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerTerminatedNCT02766140Phase 3
- Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal CancerStatus unknownNCT02762474Phase 1/2
- Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck CancerActive, not recruitingNCT02760667Phase 2
- Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant ChemotherapyStatus unknownNCT02753140Phase 2
- Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung CancerStatus unknownNCT02743923Phase 3
- Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose EscalationStatus unknownNCT02741856Phase 2/3
- Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the PancreasStatus unknownNCT02739633Phase 2
- Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic CancerStatus unknownNCT02739529Phase 1
- Paclitaxel Detection in NSCLC Treated With TC RegimenTerminatedNCT02737709Phase 2
- Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02733380Phase 2
- Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung CancerCompletedNCT02733250Phase 1/2
- A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. MalignanciesCompletedNCT02730481Phase 1
- A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced DiseaseTerminatedNCT02730091Phase 3
- Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With ChemotherapyCompletedNCT02728492Phase 1
- Protocol for the Treatment of Metastatic Ewing SarcomaCompletedNCT02727387Phase 2
- Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal CancerCompletedNCT02725424Phase 2
- Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven MedulloblastomaActive, not recruitingNCT02724579Phase 2
- PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)CompletedNCT02723877Phase 1/2
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder CancerWithdrawnNCT02718742Phase 2
- Phase II Trial for the Treatment of Relapsed OsteosarcomaTerminatedNCT02718482Phase 2
- Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic CancerStatus unknownNCT02717091Phase 2
- Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)TerminatedNCT02707328Phase 1
- Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer PatientsCompletedNCT02707159Phase 2
- Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical CancerStatus unknownNCT02703961Phase 3
- Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFRStatus unknownNCT02691871Phase 1
- Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast CancerCompletedNCT02687490Phase 2
- Denosumab as an add-on Neoadjuvant Treatment (GeparX)CompletedNCT02682693Phase 2
- Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerCompletedNCT02672475Phase 1
- Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.TerminatedNCT02670317Phase 2
- Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasStatus unknownNCT02665702Phase 2
- A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal FunctionCompletedNCT02665039Phase 2
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
- Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALLStatus unknownNCT02660762Phase 2
- Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung CancerTerminatedNCT02644252Phase 3
- Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCCStatus unknownNCT02639858Phase 2
- A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerWithdrawnNCT02637375Not applicable
- ACY-1215 + Nab-paclitaxel in Metastatic Breast CancerCompletedNCT02632071Phase 1
- Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory CancerCompletedNCT02630199Phase 1
- Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic AnalysisCompletedNCT02628951Phase 2
- Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 VariationsCompletedNCT02628613Phase 2
- Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02628132Phase 1/2
- Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric CancerStatus unknownNCT02623153Phase 2
- Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02621970Phase 3
- Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCsWithdrawnNCT02621190Phase 2
- Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic CancerCompletedNCT02620800Phase 1
- Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic MelanomaActive, not recruitingNCT02617849Phase 2
- Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast CancersStatus unknownNCT02616848Phase 1
- PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric AdenocarcinomaCompletedNCT02615730Phase 1/2
- Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02610556Phase 2
- [18F]FLT PET/CT in Rb+ Metastatic Breast CancerActive, not recruitingNCT02608216Phase 1
- CCRT for Esophageal Cancer.CompletedNCT02607982Phase 2
- Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by SurgeryWithdrawnNCT02607423Phase 2
- Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and SunitinibCompletedNCT02607332Phase 2
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMFCompletedNCT02602028Phase 4
- A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast CancerCompletedNCT02599363Phase 1
- Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast CancerTerminatedNCT02598310Phase 2
- A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid TumorsCompletedNCT02596503Phase 1
- Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical CancerStatus unknownNCT02595554Phase 3
- Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell LymphomaWithdrawnNCT02595242Phase 1
- Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast CancerCompletedNCT02594371Phase 3
- Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+TerminatedNCT02593708Phase 1
- Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaCompletedNCT02588443Phase 1
- COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AFWithdrawnNCT02582190Phase 3
- Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDSStatus unknownNCT02576301Phase 1/2
- TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsCompletedNCT02574663Phase 1
- A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell CarcinomaStatus unknownNCT02570893Phase 3
- Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast CancerWithdrawnNCT02569489Phase 1